AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Calidi Biotherapeutics Stock Soars 174.93% on Precision Medicine Hype
Generated by AI AgentAinvest Pre-Market Radar
Wednesday, Jul 9, 2025 8:15 am ET1min read
On July 9, 2025, Calidi's stock surged by 174.93% in pre-market trading, marking a significant milestone for the company.
Calidi Biotherapeutics has been at the forefront of developing a precision genetic medicine platform designed to revolutionize cancer treatment. The company's innovative approach utilizes engineered viruses to precisely deliver genetic medicine to cancer sites, addressing both primary tumors and metastatic sites. This technology has the potential to transform the landscape of cancer treatment, given the projected 35 million annual cancer cases by 2050.
This year,
has presented compelling preclinical data at two of the most influential oncology conferences, further validating the potential of its platform. The company's efforts have garnered attention and support, positioning it as a leader in the field of precision genetic medicine.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
SEALSQ Surged 8.29% Driven by 2026–2030 Roadmap for Silicon-Based Quantum Computing Systems
Dec.19 2025
Serve Robotics (SERV) Surges 5.97% on Bullish Oppenheimer Note
Dec.19 2025
AXT Inc. shares surge 13.35% on renewed earnings upside speculation amid supply chain adjustments
Dec.19 2025
PROK surged 5.11% on Dec. 19 2025 after HC Wainwright upgraded to Buy rating
Dec.19 2025
Tesla shares surge 3.45% as SpaceX orders 1,000-2,000 Cybertrucks for Starbase facility.
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet